| Malignant neoplasm of breast
Aromasin vs Truqap
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Aromasin vs Truqap with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTruqap has a higher rate of injection site reactions vs Aromasin based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Truqap but not Aromasin, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aromasin
Truqap
At A Glance
Oral
Daily
Aromatase inactivator
Oral
Twice daily (4 days on, 3 days off)
AKT inhibitor
Indications
- Malignant neoplasm of breast
- Advanced breast cancer
- Malignant neoplasm of breast
Dosing
Malignant neoplasm of breast, Advanced breast cancer 25 mg orally once daily after a meal; increase to 50 mg once daily after a meal when administered with a strong CYP 3A4 inducer.
Malignant neoplasm of breast 400 mg orally twice daily (approximately 12 hours apart) with or without food, for 4 days followed by 3 days off, in combination with fulvestrant; continue until disease progression or unacceptable toxicity.
Contraindications
- Known hypersensitivity to exemestane or any excipient
- Severe hypersensitivity to capivasertib or any of its components
Adverse Reactions
Most common (>=10%) Hot flushes, fatigue, arthralgia, headache, insomnia, increased sweating
Serious Cardiac ischemic events (myocardial infarction, angina, myocardial ischemia), cardiac failure, clinical fractures
Postmarketing Hypersensitivity, hepatitis including cholestatic hepatitis, paresthesia, tendon disorders including tendon rupture and tendonitis and tenosynovitis, acute generalized exanthematous pustulosis, urticaria, pruritus
Most common (>=20%) Diarrhea, cutaneous adverse reactions, increased random glucose, decreased lymphocytes, decreased hemoglobin, increased fasting glucose, nausea, fatigue, decreased leukocytes, increased triglycerides, decreased neutrophils, increased creatinine, vomiting, stomatitis
Serious Cutaneous adverse reactions, diarrhea, pneumonia, vomiting, pyrexia, hyperglycemia, hypersensitivity, fatigue, renal injury, second malignancy
Pharmacology
Aromatase inactivator; exemestane is an irreversible steroidal aromatase inactivator that acts as a false substrate for the aromatase enzyme, binding irreversibly to the active site ('suicide inhibition') and significantly lowering circulating estrogen concentrations in postmenopausal women without affecting adrenal corticosteroid or aldosterone biosynthesis.
Capivasertib is a pan-AKT inhibitor that blocks all three serine/threonine kinase AKT isoforms (AKT1, AKT2, AKT3), inhibiting phosphorylation of downstream AKT substrates and suppressing tumor growth driven by PIK3CA/AKT1/PTEN pathway alterations.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aromasin
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Truqap
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Aromasin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Truqap
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Aromasin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Truqap
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Aromasin Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AromasinView full Aromasin profile
TruqapView full Truqap profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.